ClinicalTrials.gg
CompletedNCT02970630Updated Mar 1, 2019

Envarsus® Once Daily With Everolimus in Elderly Kidney Transplant Recipients: Pharmacokinetic and Clinical Study

A Phase 2 interventional study of Tacrolimus and Everolimus in Kidney Transplantation, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 6 sites in Italy. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2019-03-01.

Sponsored by Chiesi Farmaceutici S.p.A. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
28
Allocation
Not applicable
Ages
60 Years and older
Sex
All
01

Study summary

Prospective, single-arm, open-label, multicentre study with the principal aim to estimate tacrolimus pharmacokinetic parameters in elderly de-novo kidney transplant recipients of ECD (Extended Criteria Donor) kidney grafts treated with Envarsus® prolonged release tablets in combination with everolimus tablets.

02

Conditions studied

  • Kidney Transplantation

Keywords

  • prophylaxis
03

In context

Lead sponsor

Chiesi Farmaceutici S.p.A. is the lead sponsor of 185 studies on the registry; 22 are open to participants now.

Of its 18 completed or terminated interventional studies of FDA-regulated products, 11 (61%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject's written obtained prior to transplant intervention and prior to any study-related procedures;
  2. Caucasian male or female subjects aged 60 or older who are receiving a primary or secondary single or dual renal transplant from a blood group compatible deceased donor;
  3. Patients who are planned to receive a renal allograft by Extended Criteria Donor (ECD);
  4. Patients capable of understanding the purposes and risks of the study, who can give written informed consent and who are willing to participate in and comply with the study;
  5. Patients with low to standard immunological risk, who had a PRA (Panel Reactive Antibody) ≤ 20% (PRA testing according to centre's practice);
  6. (BMI) between 15 and 35 kg/m2 extremes inclusive;
  7. Women must be (physiologic menopause defined as "12 consecutive months of amenorrhea") or permanently sterilized (e.g. tubal occlusion, hysterectomy or bilateral salpingectomy) to be enrolled in the study.

Exclusion criteria

Exclusion Criteria:

  1. Recipients of any transplanted organ other than a single or dual kidney;
  2. Patients unable or unwilling to provide ;
  3. Male subjects with females partner of UNLESS they or their partner are willing to use a reliable method of (see below for details) from the time of first dose administration and until 8 weeks after the last dose of study drugs. Male subjects with partners of non-childbearing potential are not required to use contraception.

    Reliable methods of contraception for male subjects and their partner of childbearing potential must be one of the following:

    1. Placement of an intrauterine device or intrauterine system
    2. Hormonal contraception (implantable, patch, oral)
    3. Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical vaults/caps) with spermicidal foam/gel/film/cream/suppository.
    4. Male sterilization (with the appropriate post-vasectomy documentation of the absence of sperm in the ejaculate "True abstinence" is acceptable only if it is in line with the preferred and usual lifestyle of the subject.
  4. Recipients of a bone marrow or stem cell transplant;
  5. Recipients of a kidney from a cardiac death donor;
  6. Recipients of a kidney from an ABO (0, A and blood cell types) incompatible donor;
  7. Recipients having pre-transplant donor specific anti-HLA (Human leukocyte antigen antibodies) (DSA) or who lost the first kidney transplant because of acute rejection;
  8. Recipients of a kidney with an anticipated cold ischemia time ≥ 24 hours;
  9. Recipients positive for virus (HCV-RNA positive) and/or Virus (HBV-DNA or HBsAg positive);
  10. Recipients positive for (HIV-Ab positive);
  11. Patients with a current or a history of malignancy (within the past 5 years), except basal or non- squamous cell carcinoma of the skin that has been treated successfully;
  12. Patients with uncontrolled concomitant infection, a systemic infection requiring treatment, or any other unstable medical condition that could interfere with the study objectives;
  13. Patients with severe diarrhoea, vomiting, active peptic ulcer or gastrointestinal disorder that may affect the absorption of study drugs;
  14. Patients with a white blood cell count ≤ 2.8x109/L unless the (ANC) is ≥ 1.0x109/L;
  15. Patients with a count ≤ 50.0x109/L;
  16. Patients with (AST) or alanine aminotransferase (ALT) enzyme levels > 3 times the during the 30 days prior to the transplant procedure;
  17. Patients who were treated with any other agent in the three months prior to enrolment;
  18. Patients who received any investigational new drug, or participated in clinical study within the last 8 weeks;
  19. Patient planned to receive an induction therapy different from rabbit ATG (Anti-thymocyte globulin) alone or patients who did not start rabbit ATG induction therapy after transplant;
  20. Patients who are already on drugs the day before transplantation, except ATG as per protocol;
  21. Patients who are planned to receive therapy with any immunosuppressive agent other than those prescribed in the study;
  22. Patients with a known to , tacrolimus or everolimus or sirolimus or any of the present in study drugs formulations;
  23. Patients with hypersensitivity to macrolides;
  24. Patients with any form of substance abuse, psychiatric disorder or a condition that, in the opinion of the Investigator, may invalidate communication with the Investigator;
  25. Subjects unlikely to comply with the study protocol or unable to understand the nature and scope of the study but also the possible benefits or unwanted effects of the study treatments;
  26. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Envarsus once a day, everolimus b.i.d.

    Tacrolimus tablets at starting dose of 0.07 mg/kg/day will be administered once daily in the morning. Everolimus tablets at starting dose of 2 mg/day (1 mg b.i.d.) will be administered twice daily, every 12 hours.

    Drug: Tacrolimus · Drug: Everolimus

Interventions

06

What researchers measure

Primary outcomes

  1. Tacrolimus Area Under the curve at 24 hours (AUC24)

    Time frame: 10 days

  2. Tacrolimus Minimum whole blood concentration (Cmin)

    Time frame: 10 days

  3. Tacrolimus Cmin/daily dose

    Time frame: 10 days

  4. Tacrolimus AUC24/daily dose

    Time frame: 10 days

Secondary outcomes

  1. Tacrolimus within-patient variability of blood trough level

    Time frame: from day 3 to month 6

  2. Time to reach therapeutic exposure to tacrolimus

    Time frame: from day 3 to month 6

  3. Number of dose adjustments

    Time frame: from day 3 to month 6

  4. Total daily dose

    Time frame: from day 3 to month 6

  5. Renal function using estimated glomerular filtration rate

    Time frame: from day 1 to month 6

  6. Treatment failure rate

    Time frame: from day 1 to month 6

  7. Delayed graft function

    Number of days between the first and the last renal replacement session

    Time frame: from day 1 to month 6

  8. Acute rejection requiring treatment

    Time frame: from day 1 to month 6

  9. Biopsy proven acute rejections

    Time frame: from day 1 to month 6

  10. Tacrolimus Maximum whole blood concentration (Cmax)

    Time frame: 10 days

  11. Tacrolimus Tmax (time that the drug is present at the maximum concentration in serum)

    Time frame: 10 days

  12. Tacrolimus Average whole blood drug concentration (Cave)

    Time frame: 10 days

  13. Tacrolimus % fluctuation

    Time frame: 10 days

  14. Tacrolimus % swing

    Time frame: 10 days

  15. Tacrolimus linear correlation coefficient between Cmin and AUC24

    Time frame: 10 days

  16. Adverse Events

    Time frame: from screening to month 6

  17. Serious Adverse Events

    Time frame: from screening to month 6

  18. Number of opportunistic infections

    Number of opportunistic infections

    Time frame: from screening to month 6

07

Study locations

6 sites
  • Ospedale Ca' Granda - Niguarda
    Milano, Italy
  • Ospedale Maggiore Policlinico
    Milano, Italy
  • Azienda Ospedaliera di Padova
    Padova, Italy
  • Policlinico "A. Gemelli"
    Rome, Italy
  • Policlinico "Le Scotte"
    Siena, Italy
  • Azienda Ospedaliera S. Giovanni Battista
    Torino, Italy
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2017 to primary completion in Feb 2018, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2016
First posted
Nov 22, 2016
StartActual
Jan 2017
Primary completionActual
Feb 22, 2018
CompletionActual
Feb 22, 2018
Last update
Mar 1, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 1, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02970630
Collaborators
Cromsource
Responsible party
Sponsor
First posted
Nov 22, 2016
Start date
Jan 2017
Primary completion
Feb 22, 2018
Completion
Feb 22, 2018
Last update
Mar 1, 2019

Study contacts

Paolo Rigotti, MD
principal investigator · Az Osp Padova, Osp. Civile Padova

Oversight

Data monitoring committee
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tacrolimus · Everolimus

Start the discussion